Introduction. Following laboratory studies on new potential chemotherapy for Acanthamoeba keratitis,
Acanthamoeba keratitis is a sight-threatening infec tion. Until recently, there has been a limited medical, therapeutic armamentarium. Although a diverse range of drugs has been suggested for treatment of this disease, medical cure was first reported in 1985 with a combination of propamidine and neomycin. 1 The limited overall success of this combination has necessitated a continued quest for alternative, improved therapy. 2 -4 In one study of in vitro sensitivity of corneal isolates of Acanthamoeba to a range of candidate drugs, chlorhexidine was found to be the most active single acanthamoebicidal compound; it was also shown to be effective in a pilot study involving two patients with CUlture-proven infection. 4 Others have subsequently shown chlorhexidine to be acantha moebicidal in vitro. 5 , 6 The related compound polyhexamethylene biguanide (PHMB) is also acanthamoebicidal and its use can result in early and effective medical treatment. 2 , 3 PHMB is not licensed, however, for medical use? although it has gained approval for inclusion as a disinfectant in certain cold-chemical soft contact lens solutions.
Chlorhexidine is a bis-biguanide while PHMB is a polymeric biguanide. Both these compounds are effective acanthamoebicides. They are thought to act via interaction between the electropositive biguanide groups and the plasma membrane; the drugs may compromise the integrity of the mucopolysaccharide plug that seals the ostiole of the cyst, although other factors are likely to be involved. The lethal action of these compounds is due primarily to the irreversible loss of essential cellular components through the damaged plasmalemma of the amoeba. Cytoplasmic precipitation is a secondary event. Mole for mole, the D. SEAL ET AL. polymeric biguanide should be more effective than the bis-biguanide, but non-specific binding due to residual positive charges on the polymer may reduce the activity of the PHMB, relative to chlorhexidine, in the presence of anionic charges. This phenom enon, however, has yet to be proven in vivo within the cornea.
The findings are presented of a multi-centre study evaluating the effect of continuous topical treatment with chlorhexidine, in combination with propamidine (as Brolene), of 12 cases of culture-proven Acantha moeba keratitis as first-line therapy.
METHODS

Patients
All 12 contact-lens-wearing patients (Table I) had the clinical diagnosis of Acanthamoeba keratitis confirmed by isolation of the protozoan from corneal scrape or biopsy. None of the 12 was treated with any other known acanthamoebicidal drug either prior to presentation or during the course of the disease. All 12 patients were treated with topical chlorhexidine (di)gluconate (0.02%) and propamidine (as Brolene, 0.1 %), and were followed up for at least 6 months following cessation of treatment. No patient who commenced the therapy described was withdrawn from the study. Brief histories of two patients (nos. 1 and 6) reported here have been recorded else where. 4 , 8 Isolation of Acanthamoeba All 12 patients had corneal scrapes cultured for Acanthamoeba. These were initially inoculated onto non-nutrient agar plates, seeded with Gram-negative coliform bacteria. 9 , l o The plates were incubated at 25°C or 32 °C for at least 7 days. In Glasgow, a wet film preparation of the corneal scrape was also examined using bright field and/or phase-contrast microscopy. lO Isolates from Leeds and Manchester were for warded to the Tennent Institute, Glasgow, for drug sensitivity testing. This ensured adequate quality control since the same method with identical assay conditions was used for all isolates.
Drug Sensitivity Testing
All 12 Acanthamoeba isolates from the cornea of each patient were tested as previously described. 4 Briefly, 100 I.d containing approximately 2 X 10 4 trophozoites or cysts was instilled into each well of microtitre plates; 100 J-li aliquots of doubling dilutions (100-0.8 J-lg/ml) of the following cationic surfactants or drugs were added: chlorhexidine (di)gluconate, alexidine (a related bis-biguanide), polyhexamethylene biguanide, propamidine isethio nate, pentamidine isethionate, hexamidine isethio nate and neomycin sulphate. Sealed plates were mixed gently for 10 minutes on a plate rotator and incubated for 48 hours in air at 32°C.
After removal of residual drug and instillation of a defined medium, plates were reincubated for a further 48 hours. During this time wells were inspected microscopically for the lowest concentra tion of drug that resulted in complete lysis or degeneration of trophozoites (minimum trophozoite amoebacidal concentration, MTAC) or, for cysts, the lowest concentration of test compound that resulted in no excystment (minimum cysticidal concentration, MCC).
RESULTS
Patients were started on intensive 3 day dosing regimens, with chlorhexidine (at 200 J-lg/ml, 0.02 % ) and propamidine (as Brolene, at 1000 J-lg/ml, 0.1 %) drops being applied every other hour day and night for 3 days. On completion of this regimen, the dosage was reduced to 2-hourly by day for 4 weeks, followed by 3-hourly by day for 4 weeks and then 4-hourly by day, for a further period until all signs and symptoms of the infection had regressed. Therapy was with drawn when the eyes appeared uninflamed and when no clinical signs suggestive of continuing infection were observed. Ancillary treatment included flurbi profen (100 mg oral t.d.s.) for pain relief, mydriasis and a non-steroidal anti-inflammatory effect.
Patients noted early reduction in the severity of their symptoms with an early symptom-free chemo therapeutic effect gained at a mean time of 3 weeks (Table II) . The signs resolved or stabilised in a mean time of 11 weeks (range 5-28 weeks), with resultant anterior stromal scarring in some patients.
Patients received treatment for between 2 and 6 months. One patient (no. 4) ignored medical advice and stopped treatment at 2 months, but remained in good vision without recrudescence up to 10 months later (Fig. 1) . With one exception (no. 2), all patients recovered 6/9 vision; patient no. 2 developed anterior stromal scarring which reduced acuity to 6/18 part with best refraction. All 12 patients were closely observed for symptoms and signs suggestive of drug toxicity to the conjunctival and corneal epithelium and the stroma. No clinical manifestations of such a toxic response were observed, albeit the degree of inflammation present on initial presentation was considerable.
A patient (no. 1) with atopy, psoriasis and blepharitis developed a secondary bacterial keratitis at 11 weeks which progressed rapidly to perforation despite appropriate anti-microbial chemotherapy. 4 A penetrating keratoplasty was performed but culture yielded no amoebal growth. Chlorhexidine and propamidine were continued with fortified gentami cin 1.5% and cefuroxime 5%. The graft did not become reinfected with Acanthamoeba. Four months later a further episode of bacterial keratitis developed around two sutures in the graft. This responded to supervised, intensive topical antibiotics. Subsequently the visual acuity recovered to 6/6 with best correction.
Non-toxic complications of combination therapy are given in Table II . Three patients (nos. 6, 9 and 12) developed marked stromal infiltration at the site of the infection 10-14 days following commencement of therapy (Fig. 2) . This was treated in one patient (no. 12) with topical steroid drops and resolved within 3 days; in the other patients (nos. 6, 9), no additional therapy was employed when the infiltrate resolved spontaneously after 2 weeks. The chlorhex idine and propamidine regimen continued through out in all three patients.
A late immuno-inflammatory complication devel oped in two patients (no. 2, Fig. 3 ; no. 9) with an 'apparent' relapse of the infection at the site of the original stromal scarring. In one case (no. 9) the lesion was scraped but yielded no growth of Acanthamoeba; chlorhexidine and propamidine were restarted until lack of viable amoebae was confirmed, but this therapy was without success. The lesion resolved, however, in several days when topical steroids were introduced. For the other case (no. 2), steroids had been used in low dosage in the preceding months and were similarly effective when given in high dosage concurrently with chlorhexidine and propamidine. In this patient there was an increase in corneal opacity due to more marked anterior corneal stromal oedema which was identi fied at a routine visit; the visual acuity was reduced to 6/36 and the overlying epithelium showed irregu larity without frank ulceration.
Acanthamoeba Sensitivity Tests Drug sensitivity data for trophozoites and cysts of the 12 Acanthamoeba isolates against chlorhexidine, alexidine, PHMB, propamidine, pentamidine and hex ami dine are shown in Fig. 4 . For trophozoites, chlorhexidine was the most active compound (modal MTAC, 1.6) followed by PHMB (modal MTAC, 3.2), while for the diamidines, propamidine was the most active (modal MTAC, 6.3). The Vahlkampfia sp. isolated from patient no. 4 was similarly sensitive to both chlorhexidine and propamidine.
For cysts, chlorhexidine, alexidine and PHMB yielded similar effects (modal MCC, 6.3) (Fig. 4a) . Propamidine, pentamidine and hexamidine showed less sensitivity (modal MCC, 12.5, 25.0, 12.5 respec tively (Fig. 4b) .
For neomycin, all trophozoites with the exception of one case 4 (no. 1) were sensitive (MTAC, 10 fJ-g/ml); conversely, cysts from 11 of 12 cases were resistant to clinically achievable concentrations (case no. 9 was sensitive, with an MCC of 10 fJ-g/ml).
DISCUSSION
All 12 patients with corneal culture-proven Acantha moeba keratitis had been wearing soft contact lenses. Nine of the 12 (75 %) had been wearing ionic, high water content lenses classified by the US Food and Drug Administration (FDA) as group 4. Two had been wearing non-ionic, low water content (FDA group 1) lenses. Data pertaining to the remaining contact lens type was unavailable. Similar reporting of an association between group 4 contact lenses and Acanthamoeba keratitis has been made previously by our group for five patients 11 , 12 and by others for at least 19 of 35 patients. 13 Nine patients had been recommended a chlorine disinfection tablet system (Softab, Alcon). Previous reports ll -13 have high lighted the association between Acanthamoeba ker atitis and the use of chlorine-based systems, which are . . A h b
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Effectivity of therapy was influenced by the time taken to establish the definitive diagnosis. Resolution gradually occurred within 4 weeks. There was relief of pain, photophobia and lid oedema within 1 week if the clinical diagnosis had been made early. 16 Early resolution at 2 weeks was apparent with disruption of the previously infiltrated epithelial layer, when the perineural inflammatory infiltrate could be seen resolving. Late resolution included the development of sub-epithelial anterior stromal scarring in an otherwise normal eye; this was recorded as occurring between 4 and 28 weeks after initiation of the combination therapy. Therapy involved courses of 2 to 7 months; no patient required additional anti-Acanthamoeba drugs. One patient (no. 1) underwent keratoplasty, as a result of secondary bacterial infection, with graft survival and visual acuity of 6/6 after 2 years. This compares with previous experience when tropho zoites were identified in corneas at the time of keratoplasty, 17 when graft survival was limited to 20% at 2 years whilst drugs other than cationic antiseptics were used.
A diverse range of drugs and regimens have been used in an attempt to identify a therapy for Acanthamoeba keratitis which would provide con sistent resolution of the condition. 4 One such treatment combined propamidine with neomycin. 1 Using this combination, approximately 50% of patients were not cured medically 18 and continued to suffer severe pain and gradual destruction of the cornea. This was probably due to both of these drugs being relatively ineffective against Acanthamoeba cysts and to resistance of some strains to both propamidine and neomycin. 4 Such resistance has not as yet been experienced in a considerable number of patients treated with PHMB in combination ther apy, 1 9 or hex ami dine as monotherapYZ o -albeit only 2 patients have been successfully treated with the latter drug. All 12 isolates were sensitive to hexamidine, which can thus be considered an alternative aromatic diamidine for ocular use. Since in our experience ocular isolates appear more sensitive to commercially available formulations of propamidine (as Brolene) than to those containing hexamidine (Desmodine), we cannot recommend that the latter be used as a first-line drug 21 if Brolene is available. We suggest, however, that drug sensi tivity tests should always be performed as soon as possible following initiation of treatment for Acanthamoeba keratitis.
Considerable care was taken in each of the 12 cases to look clinically for toxic effects related to use of either chlorhexidine or propamidine, but no such reaction was perceived. Localised anterior stromal infiltrate at the site of the infection developed in three patients after 10 days of treatment (Fig. 2) . This may have been consequent to release of toxic cellular components of Acanthamoeba into the cornea as a result of the rapid acanthamoebicidal effect of chlorhexidine. This localised effect resolved after 2 Use shown to prevent caries; non-toxic weeks in two patients without topical steroid therapy but with continuing chlorhexidine, and after several days in one other who was given steroids.
The immuno-pathogenesis of the late inflamma tory phenomenon in the cornea experienced in two patients at 6 months has been neither recognised nor recorded previously. This effect (Fig. 3) settled quickly with steroids. Such features of this late effect are known to occur in association with other infections of the cornea. With Onchocerca volvulus punctate keratitis, for example, an inflammatory infiltrate comprising lymphocytes and eosinophils with concomitant localised oedema 22 was a common feature of diethylcarbamazine-treated patients, the reaction being consequent to a cell-mediated immune response to the dead microfilariae, which were localised in the centre of ill-defined opacities.
The development of such cell-mediated immuniti 3 to the presence of Acanthamoeba antigens in the cornea may also be responsible for the severe scleritis suffered by some patients with chronic Acanthamoeba keratitis , 24 which itself may be immuno-inflammatory in origin and usually requires high-dose steroid therapy to suppress it. Pineda and Dohlman 25 have recently concluded that the role of steroids in Acanthamoeba infection is ambiguous, while D' Aversa et al. 26 have advised against their use in acute infection, because of the risk of compromis ing the host inflammatory response against Acantha moeba; these workers reserve steroids for later complications. Our experience suggests that steroids have a role in controlling late immuno-inflammatory responses, when the amoebae have been killed and antigen remains bound to the corneal stroma, but this aspect clearly requires further elucidation.
Cellular toxicity from chlorhexidine, as described in the studies referred to in Table III and using various animal models, 27 --42 was not seen in any of the treated patients. Some of these animal studies were performed on albinos, however, so findings must be interpreted with caution; 43 use of albinos is contra-indicated for toxicity studies, these animals having multiple biochemical defects. Furthermore, these observations are consistent with the safe use of chlorhexidine which has been extensively recorded from dental practice in humans. Although the physiology and biochemistry of oral mucus are different to those of the eye, there is no reason to suggest that chlorhexidine at the given concentration is not a safe therapeutic agent for the treatment of Acanthamoeba keratitis. It should be noted, how ever, that chlorhexidine is not completely without toxicity. It is toxic for certain mammalian cells when used at concentratjons of 1 % or greater (Table III) .
It is toxic to neuroepithelial cells at lower concentra tions. Thus, it must not come into contact with the retina or middle ear, 44 nor must it have tissue D. SEAL ET AL. involvement in neurosurgery. These features do not appear to influence recovery from Acanthamoeba keratoneuritis, and loss of corneal sensation does not appear to follow this condition, or its treatment with chlorhexidine.
Effective treatment of Acanthamoeba keratitis has been provided by combination therapy which includes polyhexamethylene biguanide (PHMB)?· 3 . 45 This demonstrates the usefulness of the cationic antiseptics as a class of drug for treatment of Acanthamoeba keratitis. PHMB, how ever, is manufactured principally as an industrial grade sterilant. It is used in cosmetics and soaps as a preservative, as an algastatic compound in swimming pools, and as a constituent of some contact lens disinfecting fluids. Unlike chlorhexidine? it is not licensed for therapy of infectious disease because of a paucity of clinical trials and toxicity studies in humans. Chlorhexidine has a persistent binding effect on tissue for up to 24 hours after application. It is a smaller molecule than PHMB and may permeate better into the corneal stroma. The findings from this study, suggested but not proven from Iowa, 46 have shown that chlorhexidine, in combina tion with propamidine, provides rapid and successful therapy for the treatment of Acanthamoeba infection of the cornea. This will also be a useful addition to treatment regimens for countries where contact lenses are becoming widely available. 47 . 48 
